|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | +67.63% |
| 05-04 | Arzneiwerk AG VIDA Auditor Raises 'Going Concern' Doubt | CI |
| 05-04 | Arzneiwerk AG VIDA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: TELES
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 5.375 | 43.56 | 24.31 | 8.477 | 3.584 | 2.481 |
| Change | - | 710.55% | -44.2% | -65.13% | -57.72% | -30.78% |
| Enterprise Value (EV) 1 | 4.623 | 43.17 | 24.27 | 19.53 | 4.095 | 6.176 |
| Change | - | 833.85% | -43.79% | -19.51% | -79.04% | 50.82% |
| P/E | 6.52x | -163x | -14.3x | -2.94x | -4.29x | -4.4x |
| PBR | 404x | 27.1x | 64.1x | -1.66x | - | - |
| PEG | - | 1x | -0x | -0x | 0.1x | 0.1x |
| Capitalization / Revenue | 1.91x | 17.3x | 12.7x | 0.14x | 17.3x | 36.2x |
| EV / Revenue | 1.64x | 17.1x | 12.6x | 0.33x | 19.8x | 90.1x |
| EV / EBITDA | -60.2x | -186x | -17.6x | -11.5x | -5.61x | -19.2x |
| EV / EBIT | -48.4x | -166x | -15.4x | -8.04x | -5.56x | -19x |
| EV / FCF | -5.32x | -203x | - | 43.9x | -3.9x | -17.1x |
| FCF Yield | -18.8% | -0.49% | - | 2.28% | -25.6% | -5.86% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.1887 | -0.0429 | -0.2719 | -0.462 | -0.134 | -0.0905 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 2.818 | 2.52 | 1.921 | 59.28 | 0.2071 | 0.0685 |
| EBITDA 1 | -0.0768 | -0.2315 | -1.378 | -1.705 | -0.7299 | -0.3223 |
| EBIT 1 | -0.0956 | -0.2599 | -1.576 | -2.429 | -0.7364 | -0.3247 |
| Net income 1 | 0.8245 | -0.2675 | -1.695 | -2.88 | -0.8356 | -0.5638 |
| Net Debt 1 | -0.7516 | -0.3912 | -0.042 | 11.06 | 0.5104 | 3.695 |
| Reference price 2 | 1.2300 | 7.0000 | 3.9000 | 1.3600 | 0.5750 | 0.3980 |
| Nbr of stocks (in thousands) | 4,370 | 6,223 | 6,233 | 6,233 | 6,233 | 6,233 |
| Announcement Date | 4/9/21 A | 4/14/22 A | 12/22/23 A | 4/30/24 A | 11/24/25 A | 5/4/26 A |
1EUR in Million2EUR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 11.3x | 1.32x | 4.18x | 6.99% | 224B | ||
| 11.03x | 2.59x | 6.85x | 5.64% | 208B | ||
| 13.87x | 2.22x | 5.7x | 3.95% | 159B | ||
| 13.33x | 1.82x | 7.83x | 3.17% | 85.82B | ||
| 12.76x | 0.91x | 3.43x | 6.06% | 81.31B | ||
| 11.76x | 1.79x | 4.54x | 2.78% | 69.77B | ||
| 15.7x | 2.74x | 8.57x | 4.94% | 59.39B | ||
| 24.32x | 5.47x | 19.97x | 4.42% | 57.92B | ||
| 15.76x | 2.78x | 6.22x | 4.4% | 51B | ||
| Average | 14.43x | 2.41x | 7.48x | 4.71% | 110.64B | |
| Weighted average by Cap. | 13.23x | 2.17x | 6.54x | 5.12% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TLIK Stock
- TLIK Stock
- Valuation TELES
Select your edition
All financial news and data tailored to specific country editions
















